The stakes had been high for Novo Nordisk’s Phase III REDEFINE 1 clinical trial of its next-generation obesity agent CagriSema (cagrilintide 2.4mg and semaglutide 2.4mg), which has been Novo’s best hope to extend its leadership position in the fast-growing obesity market. While the topline REDEFINE 1 results were not a losing hand, they were not a full house either.
Novo Nordisk’s CagriSema Hits Mark, But Misses Target In Obesity
Efficacy for the drug came in below investors’ expectations for beating Lilly’s Zepbound, while analysts said a lower percentage of people remaining on the highest dose suggested tolerability issues.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.